ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update August 13, 2021
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID July 19, 2021
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity July 19, 2021
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development June 17, 2021
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum June 17, 2021
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections May 26, 2021
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office May 3, 2021
ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium April 26, 2021
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit April 15, 2021
